What the research shows
- Cagrilintide: 11.5% average weight loss in 68 weeks
- Retatrutide: 82.4% average liver-fat reduction in 24 weeks
- Retatrutide: 1.94% average HbA1c drop in 40 weeks
Published study results for the compound, not results from this product. For research use only.
This fixed 3mL blend is labelled with 30mg Retatrutide, an investigational GIP/GLP-1/glucagon receptor agonist, and 5mg Cagrilintide, an investigational long-acting amylin analogue. The compounds have separate research programmes; no study of this fixed Genovare blend is supplied. No batch-specific independent report is linked, so component identity, quantity and purity are unverified.
- Pack Size
- 3mL
- Product details
- Genovare Catalogue
- Pre-Filled Pen
- Premixed Aqueous
- Storage Guidance
- Follow Package Label
- 1 pre-filled Genovare research pen
- 3 pen needles
- Genovare retail packaging
Genovare Pre-Filled Pen Premixed Aqueous
SpecsRETAKLIK 2.0 Retatrutide + Cagrilintide 35mg Total (30mg + 5mg) AQ Pen
Retatrutide: 25.0% average weight loss in 80 weeks
AED 1,200 / pen
Choose your bundle
Minimum order is AED 400
25% off orders of AED 700+ with code KV25 at checkout
Order before 4 PM for same-day Dubai delivery.
UAE delivery: AED 50 below AED 1,000; free from AED 1,000
- Sold by
- Remy Research
- Brand
- Genovare
- Manufacturer
- Genovare
- Tested by
- Independent testing not supplied
Ships from Dubai
Technical Specifications
| Manufacturer | Genovare |
|---|---|
| Compound | Retatrutide + Cagrilintide |
| Catalogue strength | 35 mg total (30 mg + 5 mg) |
| Fill volume | 3mL |
| Format | Aqueous pre-filled pen |
| Pack size | 1 pen with 3 needles |
| Independent testing | Not supplied |